Author:
Wickramarachchi Dilki,Steeno Gregory,You Zhiping,Shaik Saleem,Lepsy Christopher,Xue Li
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. U.S. Food and Drug Administration/Center for Drug Evaluation and Research. Guidance for industry: immunogenicity assessment for therapeutic protein products. Forms based on FDA Drugs guidence. 2014.
2. Lamberth K, Reedtz-Runge SL, Simon J, Klementyeva K, Pandey GS, Padkjaer SB, et al. Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools. Sci. Transl. Med. 2017;9(372).
3. Mazor R, Onda M, Pastan I. Immunogenicity of therapeutic recombinant immunotoxins. Immunol Rev. 2016;270(1):152–64.
4. Mazor R, Zhang J, Xiang L, Addissie S, Awuah P, Beers R, et al. Recombinant immunotoxin with T-cell epitope mutations that greatly reduce immunogenicity for treatment of mesothelin-expressing tumors. Mol. Cancer Ther. 2015;14(12):2789–96.
5. Delluc S, Ravot G, Maillere B. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. FASEB J. 2011;25(6):2040–8.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献